SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending after news of a significant investment and partnership with Nvidia, boosting confidence in the company's AI and chip manufacturing prospects; the community is discussing the potential long-term impacts and whether this marks a true turnaround for the stock, with some speculating on future partnerships and price targets while considering possible pullbacks after the initial surge.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desk is trending amidst a significant downturn, sparking debate among investors about whether it's an oversold opportunity or a value trap. Community discussions revolve around potential reasons for the drop, ranging from analyst downgrades and competition from walled gardens like Amazon and Netflix to concerns about the company's leadership and strategic direction. Despite some defending the company's fundamentals and long-term potential, the stock's performance relative to its peers and the broader market is raising concerns.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

Cleanspark is trending as investors discuss its potential pivot towards AI and high-performance computing, sparked by recent CEO commentary. The community is analyzing key resistance levels, with many believing the stock is undervalued compared to its peers and poised for a significant rally. Bullish sentiment surrounds the stock as traders anticipate further developments in its strategic shift.

Brera Holdings Plc engages in the business of football division progression, global football player transfer service, sponsorship services, football school services, and consulting services on football projects. The company was founded on June 30, 2022 and is headquartered in Dublin, Ireland.

Brera Holdings PLC - Ordinary Shares - Class B

Brera Holdings PLC

BREA is trending due to news of a $300 million private placement to establish a Solana digital asset treasury, leading to a rebrand as Solmate. Community members are discussing the potential for a short squeeze given the low float, drawing comparisons to other crypto treasury plays like QMMM and BMNR, while also speculating on potential price movements and dilution risks.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI ($SOUN) is trending as investors discuss its potential for a short squeeze, fueled by high short interest and anticipation of positive catalysts. Community members are pointing to technical indicators suggesting a breakout, while also speculating on potential partnerships and the company's growth prospects in the AI-driven customer service sector. The stock is experiencing high options volume, with traders eyeing potential price targets amid bullish sentiment.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending amid discussions about its upcoming e-bike launch, production plans, and partnerships, including the new Georgia plant and the VW Group collaboration. Community members are actively debating the potential impacts of these developments on Rivian's future profitability and market position. Sentiment is mixed, with some expressing optimism and others voicing concerns about cash burn and competition within the EV sector.

Internet Computer (IC) is the world’s first blockchain that is capable of running at web speed at unrestrictive capacities. Built by the DFINITY Foundation, IC aims to recreate the web by supporting smart contract development at scale and changing the way people can interact using web services. Internet Computer aims to extend the public internet, so that it can be the world’s computing platform, in a decentralized manner. Internet Computer sets to revolutionalize the design of the crypto economy, with an aim to overhaul traditional software services.   The project was founded in October 2016 by Dominic WIllams and have raised a total of $121 million from investors such as Adreessen Horowitz, Polychain Capital, Multicoin Capital and such. On May 10, 2021, DFINITY launched the Internet Computer into the public domain, marking it a major milestone for ICP as it means the internet now functions as a decentralised global computer. This is marked by the release of all of the Internet Computer’s source code into the public domain, as well as ICP utility token that allows tens of thousands of community members to govern the Internet Computer network.  ICP is Internet Computer's native token. It plays three prominent roles:  1. Network Governance: Users that participate in the governance will be rewarded with ICPI 2. Production of Cycles for Compute: ICP can be converted into cycles where it is used as the transaction fee to access the network. Cycles are burned after used. 3. Rewarding Users: ICP is used as the rewards to incentivize users to participate in the network such as securing the network.

Internet Computer

Internet Computer is trending as the community awaits the full release of Caffeine AI, with many believing it will drive adoption and utility for the token. While some express excitement about potential gains and the tech's capabilities, others remain skeptical, citing concerns about marketing and competition from centralized AI solutions. Discussions also include staking rewards and comparisons to other blockchains, reflecting a mix of optimism and caution.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo ($OKLO) is trending due to renewed excitement around its potential role in powering AI data centers and recent positive news, including a partnership. The community is actively debating the stock's valuation, with some bulls targeting higher prices based on future growth prospects and bears citing the pre-revenue stage as a concern. The stock's volatility and potential for significant swings are also key discussion points.

Serve Robotics, Inc. engages in providing self-driving delivery. It designs, develops, and operates zero-emissions robots that serve people in public spaces, starting with food delivery. The company was founded by Ali Kashani, Dmitry Demeshchuk and MJ Burk Chun in 2017 and is headquartered in Redwood City, CA.

Serve Robotics Inc

SERV is trending as the robotics sector gains attention, with community members actively discussing its potential for growth and comparing it to competitors like RR.  Bullish sentiment is fueled by anticipation for upcoming earnings, potential new partnerships, and the broader adoption of robotics in delivery and other sectors. Some traders are also noting technical indicators that suggest a possible breakout.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending as investors react to news of a new Air Force contract and broader enthusiasm for the quantum computing sector, drawing comparisons to past high-growth stocks. Community members are debating the stock's valuation and potential, with some highlighting institutional ownership and others cautioning against overvaluation. Option activity is elevated, suggesting increased speculative interest in RGTI's near-term price movement.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Verastem (VSTM) Reports Q2 Loss, Misses Revenue Estimates

Verastem (VSTM) delivered earnings and revenue surprises of +54.12% and -86.36%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Gossamer Bio (GOSS) Reports Q2 Loss, Beats Revenue Estimates

Gossamer Bio (GOSS) delivered earnings and revenue surprises of +5.56% and +155.88%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Verastem (VSTM) Q2 Earnings Expected to Decline

Verastem (VSTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tempus AI's 89% Genomics Surge: Will the Momentum Keep Building?  

Shares of Verastem Oncology (VSTM) dropped 19% on Monday despite the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-announces-updated-data-partner-genfleet">announcing</a> positive updated data from the dose escalation phase of its trial for cancer therapy GFH375, conducted by its partner, GenFleet Therapeutics.In a study in China, GFH375, also known as VS-7375 in the U.S., demonstrated an overall response rate of 52% in patients with pancreatic ductal adenocarcinoma and a response rate of 42% in those with non-small cell lung cancer, the company stated.Verastem stated that data from its partner supports the advancement of its clinical program for VS-7375 in the U.S., which is slated to start in mid-2025.The company is activating sites in the U.S. for VS-7375 to begin enrollment in the trial. The study has the potential to expand globally and will evaluate the safety and efficacy of VS-7375 in patients with advanced, KRAS G12D-mutant solid tumors.The KRAS G12D mutation, a genetic alteration in the KRAS gene, is common in various cancers, particularly pancreatic cancer, colorectal cancer, and lung adenocarcinoma.As part of the collaboration between Verastem and GenFleet, Verastem has development and commercialization rights for the cancer therapy outside the GenFleet markets of mainland China, Hong Kong, Macau, and Taiwan.On Stocktwits, retail sentiment around Verastem rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:627/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_02_at_12_42_50_PM_png_7c68caaf50.webp" alt="VSTM's Sentiment Meter and Message Volume as of 1:00 p.m. ET on June 2, 2025 | Source: Stocktwits" width="627" height="64"><figcaption>VSTM's Sentiment Meter and Message Volume as of 1:00 p.m. ET on June 2, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the stock could be tanking owing to the Chinese partnership.<stembedurl>https://stocktwits.com/Universaal/message/616509493</stembedurl>According to data from Koyfin, all of the nine analysts covering the stock rate it ‘Buy’ or higher. The stock has an average price target of $15.75, representing an upside of over 150%.<a href="https://stocktwits.com/symbol/VSTM">VSTM stock</a> is down by 6% this year but up by about 55% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/meta-s-push-toward-fully-automated-ads-to-reportedly-debut-by-year-end/chkY2oMRbHJ">Meta’s Push Toward Fully Automated Ads To Reportedly Debut By Year-End</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Verastem Announces Positive Data From Cancer Trial Conducted By Partner: Retail Turns Bullish

In a study conducted in China, GFH375, also known as VS-7375 in the U.S., showed an overall response rate of 52% in patients with pancreatic ductal adenocarcinoma and 42% in those with non-small cell lung cancer.

Equity

VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval

The U.S. Food and Drug Administration on Thursday granted accelerated approval to Verastem Oncology’s (VSTM) combination therapy for adult patients with a particular type of ovarian cancer.The combination of Avutometinib capsules and Defactinib tablets, under the brand name Avmapki Fakzynja Co-pack, can now be used to <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-combination-avutometinib-and-defactinib-kras-mutated-recurrent-low">treat</a> patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior treatment.LGSOC is a rare ovarian cancer which is highly recurrent and less sensitive to chemotherapy compared to high-grade serous ovarian cancer. Approximately 6,000-8,000 women in the U.S. and 80,000 worldwide are living with this disease, as per Verastem.Avmapki Fakzynja Co-pack is the first and only FDA-approved medicine for this disease, Verastem said, while adding that the oral medicine pack is expected to be available for adult patients in the U.S. in one week.The FDA previously granted priority review to Verastem’s drug application and also designated it a breakthrough therapy and orphan drug.Late last month, the company announced a $75 million private placement. The proceeds would be used to fund the launch of the combination therapy, among other things. &nbsp;On Stocktwits, retail sentiment around Verastem rose from ‘neutral’ to ‘bullish’ over the past 24 hours while message volume remained at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:626/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_08_at_1_01_06_PM_png_213d5d0710.webp" alt="VSTM's Sentiment Meter and Message Volume as of 1:00 p.m. ET on May 8, 2025 | Source: Stocktwits" width="626" height="63"><figcaption>VSTM's Sentiment Meter and Message Volume as of 1:00 p.m. ET on May 8, 2025 | Source: Stocktwits</figcaption></figure>The stock is trading 3% higher on Thursday afternoon after a trading halt.&nbsp;<a href="https://stocktwits.com/symbol/VSTM">VSTM stock</a> has gained by about 6% this year but has fallen by about 39% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/viatris-reports-q1-earnings-above-estimates/chifqcaRbk1">Viatris Q1 Earnings Exceed Wall Street Expectations, Company Raises Full-Year Profit Outlook: Retail’s Positive</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Verastem’s Combination Therapy For Ovarian Cancer Gets FDA Approval: Retail’s Pleased

The combination of Avutometinib capsules and Defactinib tablets, under the brand name Avmapki Fakzynja Co-pack, can now be used to treat patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior treatment.

Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Womens Cancer

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced multiple oral and poster...

Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team will...

Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced its 2025 priorities and upcoming...

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

VSTM
Verastem Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest VSTM News

VSTM Verastem Inc